Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials
暂无分享,去创建一个
J. Douketis | H. Milionis | E. Giamarellos‐Bourboulis | M. Florentin | D. Sagris | E. Korompoki | G. Dalekos | G. Ntaios | A. Spyropoulos | N. Gatselis | P. Tasoudis
[1] M. Netea,et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial , 2021, Nature Medicine.
[2] Brenda J. Crowe,et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial , 2021, The Lancet Respiratory Medicine.
[3] A. Abbate,et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. , 2021, JAMA.
[4] D. Quirk,et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia , 2021, The New England journal of medicine.
[5] Saifullah Baig,et al. Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial , 2021, EClinicalMedicine.
[6] P. Libby,et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial , 2021, The Lancet.
[7] E. Vicaut,et al. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial , 2021, Clinical Microbiology and Infection.
[8] M. Vlychou,et al. Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19 , 2021, European Journal of Internal Medicine.
[9] Y. Mehta,et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial , 2021, The Lancet Respiratory Medicine.
[10] I. Douglas,et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia , 2021, The New England journal of medicine.
[11] L. Fabbri,et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19 , 2021, Thorax.
[12] A. Zangrillo,et al. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. , 2021, European Journal of Internal Medicine.
[13] M. Sormani,et al. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia , 2021, Journal of Allergy and Clinical Immunology.
[14] F. Montorsi,et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study , 2021, The Lancet Rheumatology.
[15] E. Vicaut,et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial , 2021, The Lancet Respiratory Medicine.
[16] Á. Avezum,et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial , 2021, BMJ.
[17] Christopher M. Horvat,et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report , 2021, medRxiv.
[18] J. Callejas-Rubio,et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study , 2021, Internal and Emergency Medicine.
[19] G. Criner,et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia , 2020, The New England journal of medicine.
[20] Cameron R. Wolfe,et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.
[21] C. Mason,et al. Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19 , 2020, iScience.
[22] N. Mackman,et al. Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality—Brief Report , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[23] L. Notarangelo,et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients , 2020, JCI insight.
[24] Samuel M. Brown,et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[25] I. Tleyjeh,et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis , 2020, Clinical Microbiology and Infection.
[26] M. Netea,et al. An open label trial of anakinra to prevent respiratory failure in COVID-19 , 2020, medRxiv.
[27] Eric A. Meyerowitz,et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.
[28] R. Porcher,et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.
[29] M. Massari,et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.
[30] Matthew D Taylor,et al. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm , 2020, Chest.
[31] P. van Paassen,et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial , 2020, The Lancet Rheumatology.
[32] S. Nopp,et al. Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis , 2020, Research and Practice in Thrombosis and Haemostasis.
[33] J. Schoones,et al. Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] C. Weber,et al. Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19 , 2020, Thrombosis and Haemostasis.
[35] J. Duggan,et al. Efficacy of tocilizumab in COVID‐19: A systematic review and meta‐analysis , 2020, Journal of medical virology.
[36] M. Lucena,et al. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study , 2020, Infectious Diseases and Therapy.
[37] Christopher M. Horvat,et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. , 2020, JAMA.
[38] D. Annane,et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[39] Á. Avezum,et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. , 2020, JAMA.
[40] Yindalon Aphinyanaphongs,et al. Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19 , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[41] Keith Sigel,et al. An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.
[42] Adeel Jamil,et al. Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis , 2020, Journal of clinical medicine.
[43] Eric Song,et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.
[44] Á. Avezum,et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 , 2020, The New England journal of medicine.
[45] John D Lambris,et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis , 2020, medRxiv.
[46] D. Andreini,et al. ST-Elevation Myocardial Infarction in Patients With COVID-19 , 2020, Circulation.
[47] Thomas J Oxley,et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young , 2020, The New England journal of medicine.
[48] Binita Shah,et al. ST-Segment Elevation in Patients with Covid-19 — A Case Series , 2020, The New England journal of medicine.
[49] M. Wintermark,et al. Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source. , 2020, European heart journal.
[50] M. Netea,et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.
[51] S. Connolly,et al. Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial , 2020, Stroke.
[52] David Berlin,et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.
[53] D. Gommers,et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.
[54] G. Ntaios. Embolic Stroke of Undetermined Source: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.
[55] R. Diaz,et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.
[56] G. Sirimarco,et al. Prevalence and Overlap of Potential Embolic Sources in Patients With Embolic Stroke of Undetermined Source , 2019, Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.
[57] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[58] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[59] R. Hart,et al. Embolic Stroke. , 2017, Circulation.
[60] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.